Literature DB >> 12224305

[Treatment of patients with Graves' ophthalmopathy by immunosuppressive agent and 99Tc-MDP].

Weimin Pan1, Tianzhi Tan, Quanlin Wang, Jianguo Zheng.   

Abstract

The purpose of this study was to evaluate the efficacy of immunosuppressive agents, 99Tc-MDP and both of them in treating patients with Graves' ophthalmopathy(GO). The efficacy was evaluated by randomized controlled trial involving a total of 66 patients. In 22 patients treated with immunosuppressive agents, the general efficacy rate was 19/22, the incidence rate of serious side-effect was 8/22. In 20 patients treated with 99Tc-MDP, the general efficacy rate was 17/20, the incidence rate of serious side-effect was 2/20. In 24 patients treated with immunosuppressive agents and 99Tc-MDP, the general efficacy rate was 22/24, the incidence rate of serious side-effect was 2/24. The results suggested that in the treatment of Graves' ophthalmopathy, when satisfactory efficacy was obtained, the serious side-effect and 'rebound' of symptom could be avoided by using immunosuppressive agents in combination with 99Tc-MDP.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12224305

Source DB:  PubMed          Journal:  Sheng Wu Yi Xue Gong Cheng Xue Za Zhi        ISSN: 1001-5515


  1 in total

1.  99Tc-MDP treatment for the therapy of rheumatoid arthritis, choroidal neovascularisation and Graves' ophthalmopathy.

Authors:  Qian Wu; Yang Ni; Qingrui Yang; Hongsheng Sun
Journal:  Biomed Rep       Date:  2016-02-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.